Rezolute Inc Stock Price, News & Analysis

Rezolute, Inc. (Nasdaq: RZLT) announced it will present clinical data from its Phase 1b multiple-ascending dose study of RZ402 at The Retina Society 55th Annual Scientific Meeting, scheduled for November 2-5, 2022, in Pasadena, CA. The presentation, titled RZ402: a Novel Orally Administered Plasma Kallikrein Inhibitor to Target Diabetic Macular Edema, will be delivered by Dr. Quan Dong Nguyen on November 3, 2022, from 1:47 p.m. to 2:52 p.m. ET. Rezolute is focused on developing transformative therapies for chronic metabolic diseases.

Rezolute, Inc. (RZLT) announced a $130 million registered direct offering and private placement to fund clinical trials for RZ358 and RZ402. The fourth quarter fiscal 2022 results showed a net loss of $9.4 million, increasing from $6.5 million year-over-year. R&D expenses rose to $8.6 million, driven by clinical trial costs, while G&A expenses increased to $2.7 million. Positive developments include favorable safety data from the Phase 2b RIZE study, which showed a 75% reduction in hypoglycemia events for RZ358. The company holds $150.4 million in cash as of June 30, 2022.

Rezolute, Inc. (Nasdaq: RZLT) has announced an oral presentation at the upcoming 60th European Society for Paediatric Endocrinology (ESPE) meeting, held from September 15-17, 2022, in Rome. The presentation will focus on additional data from the Phase 2b RIZE Study of RZ358 for congenital hyperinsulinism. Dr. Hüseyin Demirbilek will present findings regarding the unmet treatment needs and glycemic responses associated with RZ358. This clinical asset is in late-stage development aimed at improving outcomes for patients with this rare metabolic disease.

Rezolute, Inc. (RZLT) has announced the promotion of Brian Roberts, M.D. to Chief Medical Officer, effective June 1, 2022. Dr. Roberts has been with Rezolute since 2017, previously serving as Senior Vice President of Clinical Development. His extensive experience includes leading clinical strategies for metabolic disease therapies. CEO Nevan Elam emphasized Dr. Roberts' integral role in advancing the company's clinical development plans, particularly for the lead asset RZ358, aimed at treating congenital hyperinsulinism. This transition aims to enhance leadership as Rezolute progresses its late-stage clinical programs.

Rezolute announced a $130 million registered direct offering and concurrent private placement, aiming to fund key developmental phases for its drug RZ358 and initiate a Phase 2 study for RZ402. Positive topline results from the Phase 2b RIZE study for RZ358 showed a significant 75% reduction in hypoglycemia events, demonstrating its potential as a monotherapy for congenital hyperinsulinism. Financially, cash reserves stand at $63.4 million, with a net loss of $11.2 million for Q3 fiscal 2022.

Rezolute, Inc. (Nasdaq: RZLT) announced a corporate update conference call on May 4, 2022, at 4:30 p.m. ET to discuss recent advancements in its drug pipeline. The call will focus on RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. Interested analysts and investors can join by calling 1-877-270-2148 (U.S.) or 1-412-902-6510 (internationally), with a live webcast available on the company's investor page. A replay will be accessible for 90 days post-event.

Rezolute, Inc. (Nasdaq: RZLT) has successfully closed its underwritten registered direct offering, raising approximately $121.9 million. The offering included 18,026,315 shares at $3.80 each and pre-funded warrants for 12,921,055 shares at $3.799 each. Proceeds will support the development of RZ358 for Congenital Hyperinsulinism and RZ402 for Diabetic Macular Edema, along with general corporate needs. Key investors include Acuta Capital Partners and Janus Henderson Investors. Notably, some warrants require stockholder approval for share increase, to be sought by June 30, 2022.

Rezolute, Inc. (Nasdaq: RZLT) has announced an underwritten registered direct offering of 18,026,315 shares at $3.80 each, alongside pre-funded warrants for 12,921,055 shares at $3.799 each. The gross proceeds are anticipated to be around $130 million. The company intends to use the funds for the development of its therapies RZ358 for Congenital Hyperinsulinism and RZ402 for Diabetic Macular Edema, and for other corporate purposes. The offering is expected to close on or about May 4, 2022.

Rezolute, Inc. announced promising results from its Phase 2b RIZE study for RZ358, targeting congenital hyperinsulinism (HI). The study revealed a significant ~75% reduction in hypoglycemia events and over 50% improvement across all patients in the high-dose cohort, with no adverse drug reactions reported. The drug showed predictable, dose-dependent results and good safety profiles, paving the way for its potential use as a monotherapy. These findings support advancing RZ358 into a Phase 3 registrational program, aiming to address the urgent need for effective treatments in HI.